Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12707588 | 1.00 | SLC17A5 (0.47) | SLC17A5MDM4TP53PPARAPPARG | |
| SCHEMBL19888241 | 0.86 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL14063754 | 0.84 | PPARA (0.58) | SLC17A5MDM4TP53PPARAPPARG | |
| SCHEMBL8139788 | 0.83 | CASP1 (0.48) | SLC17A5MDM4TP53PPARAPPARG | |
| SCHEMBL6989365 | 0.83 | CASP1 (0.48) | SLC17A5MDM4TP53PPARAPPARG | |
| SCHEMBL24037243 | 0.82 | PPARA (0.60) | SLC17A5PPARAPPARGPPARDMDM2 | |
| SCHEMBL8541445 | 0.82 | PPARA (0.60) | SLC17A5PPARAPPARGPPARDMDM2 | |
| SCHEMBL30341699 | 0.82 | PPARA (0.60) | SLC17A5PPARAPPARGPPARDMDM2 | |
| SCHEMBL12065748 | 0.82 | PPARA (0.60) | SLC17A5PPARAPPARGPPARDMDM2 | |
| SCHEMBL12267407 | 0.80 | CYP1A2 (0.40) | SLC17A5MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012975-B2 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-8012975-B2 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-7919493-B2 | A compound having a fused ecteinascidin five ring system with a 1,4 bridge; anticarcinogenic agent | PHARMA MAR, S.A. (ES) | 2011-04-05 | — | — | US | disclosed |
| US-7524956-B2 | Hemisynthetic method and new compounds | PHARMA MAR, S.A. (ES) | 2009-04-28 | — | — | US | disclosed |
| US-7524956-B2 | Hemisynthetic method and new compounds | PHARMA MAR, S.A. (ES) | 2009-04-28 | — | — | US | disclosed |
| US-7420051-B2 | Antitumor agents; microbiocides; antibiotics; forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction | PHARMA MAR, S.A. (ES) | 2008-09-02 | — | — | US | disclosed |
| US-7420051-B2 | Antitumor agents; microbiocides; antibiotics; forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction | PHARMA MAR, S.A. (ES) | 2008-09-02 | — | — | US | disclosed |
| US-7410969-B2 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2008-08-12 | — | — | US | disclosed |
| US-7410969-B2 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2008-08-12 | — | — | US | disclosed |
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | PHARMAMAR (ES) | 2008-06-19 | — | — | US | disclosed |
| EP-1287004-B1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF AN ECTEINASCIDIN COMPOUND | PHARMA MAR SA (ES) | 2005-07-27 | — | — | EP | disclosed |
| EP-1496060-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| EP-1185536-B1 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR SA (ES) | 2004-11-24 | — | — | EP | disclosed |
| EP-1289999-B1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR SA (ES) | 2004-11-17 | — | — | EP | disclosed |
| US-20040019056-A1 | Anititumoral analogs of et-743 | PHARMA MAR, S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
| US-20040002602-A1 | Synthetic process for the manufacture of an ecteinaschidin compound | PHARMA MAR, S.A. (ES) | 2004-01-01 | — | — | US | disclosed |
| EP-1289999-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2003-03-12 | — | — | EP | disclosed |
| EP-1185536-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001087894-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069862-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002602-A1 | Synthetic process for the manufacture of an ecteinaschidin compound | CIAPIN1, INHA, EMD | SLC17A5 268/4885MDM4 4547/4885TP53 4558/4885 |
| US-20040019056-A1 | Anititumoral analogs of et-743 | ETV1, ETV6, MATR3 | SLC17A5 1277/4885MDM4 2439/4885TP53 688/4885 |
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | AREG, CD68, ASGR1 | SLC17A5 1070/4885MDM4 3411/4885TP53 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.